Now showing 1 - 3 of 3
ItemNo Preview AvailableMethods for In Vivo CRISPR/Cas Editing of the Adult Murine RetinaHung, SS ; Li, F ; Wang, J-H ; King, AE ; Bui, BV ; Liu, G-S ; Hewitt, AW ; Boon, CJF ; Wijnholds, J (HUMANA PRESS INC, 2018-01-01)Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein (Cas) is used by some bacteria and most archaea to protect against viral phage intrusion and has recently been adapted to allow for efficient editing of the mammalian genome. Whilst CRISPR/Cas-based technology has been used to modify genes in mammalian cells in vitro, delivery of CRISPR/Cas system into mammalian tissue and/or organs is more difficult and often requires additional vectors. With the use of adeno-associated virus (AAV) gene delivery system, active CRISPR/Cas enzyme can be maintained for an extended period of time and enable efficient editing of genome in the retina in vivo. Herein we outline the method to edit the genome in mouse retina using a dual AAV vector -mediated CRISPR/Cas9 system.
ItemNo Preview AvailableResponse of the Rat Optic Nerve to Acute Intraocular and Intracranial Pressure ChangesZhao, D ; He, Z ; Van Koeverden, A ; Vingrys, AJ ; Wong, VHY ; Lim, JKH ; Nguyen, CTO ; Bui, BV ; Wang, N (Springer, 2019)Glaucoma is a neurodegenerative disease, characterized by the progressive death of retinal ganglion cells. Elevated intraocular pressure (IOP) is known to be an important risk factor for glaucoma; however, it is not the only force acting on the optic nerve. Intracranial pressure (ICP) also exerts an effect on the optic nerve head, effectively opposing the force applied by IOP. Indeed, this balance of forces creates a pressure gradient (or the translaminar pressure gradient) across the optic nerve head . Increasingly it is thought that the pressure difference between IOP and ICP, the translaminar pressure (TLP), may be critical for the integrity of the retina and optic nerve , and thus ICP may be an important risk factor for glaucoma [2–6].
ItemBehold the Eye in Parkinson's Disease & Alzheimer’s DiseaseLim, JK ; Li, Q ; He, Z ; Vingrys, A ; Wong, V ; Currier, N ; Mullen, J ; Bui, B ; Nguyen, C ; Bodis-Wollner, I ; Cuenca, N ; Chang, RC-C (Frontiers Media SA, 2016-11)Consequently, AD/PD patients can gradually develop vision problems. This neurological and ophthalmological disorder creates a pressing need for developing therapy to treat vision impairment in AD/PD.